Contact us   |  

Innovative Treatments of Cutaneous T Cell Lymphomas

Innovative Treatments of Cutaneous T Cell Lymphomas

28/05/2020 17:00

Speakers: Martine Bagot

Target: Health professionals
Subnetworks: Lymphoid malignancies
Disease Groups: Primary cutaneous lymphoma

Prof Martine Bagot, MD, PhD, is Professor of Dermatology and Head of the Department of Dermatology in Saint Louis Hospital, Paris University, France. This department is the largest Dermatology Department in Paris region, with classical hospitalization beds, day hospitalization, oncodermatology center, outpatients clinic, surgery and sexually transmitted department. We also have two Inserm/Paris University research teams, one in Oncodermatology and one in Inflammatory dermatoses.

Pr Bagot is responsible for a national reference center for cutaneous lymphomas and participates to many international research projects and trials in this field. One of their major recent achievement is the identification of several diagnostic and prognostic markers for cutaneous T-cell lymphoma. They have raised a new "first-in-human" targeted anti CD158k/KIR3DL2 monoclonal antibody for the treatment of cutaneous T cell lymphoma. After an achieved promising phase I, this antibody recently received FDA fast track designation for accelerated development in relapsed or refractory Sézary syndrome.

She is section editor of the Journal for Investigative Dermatology. She is author or co-author of 590 publications referenced in Pubmed. She has membership for European Dermatology Forum, European Academy for Dermatology and Venereology, European Society for Dermatological Research, International Society for Cutaneous Lymphomas, European Academy for Dermato-Oncology, EORTC Cutaneous Lymphoma Task Force, French Society for Dermatology, and French Society for Dermatological Research.